#VisualAbstract: Adjuvant pembrolizumab does not reduce health-related quality of life in patients with stage III melanoma
Click to read the study in The Lancet Oncology. Click to see previously reported survival outcomes from the same cohort.
Tag: Pembrolizumab
#VisualAbstract: Pembrolizumab improves long-term survival in patients with stage III melanoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: Liver metastases and LDH levels may be superior prognostic biomarkers for patients with metastatic melanoma
Click to read the study in JAMA Oncology.
#VisualAbstract: Lenvatinib plus pembrolizumab improves overall survival and progression free survival for advanced renal cell carcinoma treatment
1. Lenvatinib plus pembrolizumab was superior to sunitinib in overall survival for patients with advanced renal cell carcinoma. 2. Lenvatinib ...
#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH
Click to read the study in the European Journal of Cancer.
Lenvatinib plus pembrolizumab for advanced renal cell carcinoma treatment
1. Lenvatinib plus pembrolizumab was superior to sunitinib in overall survival for patients with advanced renal cell carcinoma. 2. Lenvatinib ...
#VisualAbstract: Pembrolizumab linked to longer cancer-free period in advanced MSI-H-dMMR colorectal cancer
1. In a phase 3 trial across 23 countries, Pembrolizumab displayed a longer cancer-free period when compared to the first ...
Pembrolizumab linked to longer cancer-free period in advanced colon cancer
1. In a phase 3 trial across 23 countries, Pembrolizumab displayed a longer cancer-free period when compared to the first ...
#VisualAbstract: Long-term pembrolizumab monotherapy maintains efficacy despite the occurrence of immune-related adverse events in patients with advanced melanoma
Click to read the study in European Journal of Cancer